Company profile for Medicenna Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Medicenna is a clinical stage immunooncology company advancing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™. We are developing a unique set of tunable Superkines™ that can be fused with pro-apoptotic proteins to precisely deliver potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment and cancer stem cells without harming he...
Medicenna is a clinical stage immunooncology company advancing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™. We are developing a unique set of tunable Superkines™ that can be fused with pro-apoptotic proteins to precisely deliver potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment and cancer stem cells without harming healthy cells.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
1920 Yonge St Toronto, Ontario, CA
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/10/3203073/0/en/Medicenna-Updates-MDNA11-Clinical-Trial-Results-at-the-ESMO-IO-Congress-2025-Further-Bolstering-its-Anti-Tumor-Activity-in-Advanced-Solid-Tumors.html

GLOBENEWSWIRE
10 Dec 2025

https://www.globenewswire.com/news-release/2025/11/13/3187152/0/en/Medicenna-Therapeutics-Reports-Second-Quarter-Fiscal-2026-Financial-Results-and-Provides-a-Corporate-Update.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/10/23/3172540/0/en/Updated-MDNA11-Clinical-Data-from-the-ABILITY-1-Study-to-be-Presented-at-the-European-Society-for-Medical-Oncology-ESMO-Immuno-Oncology-Congress-2025.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/10/20/3169225/0/en/Medicenna-Therapeutics-Announces-Participation-in-Upcoming-Conferences.html

GLOBENEWSWIRE
20 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159359/0/en/Medicenna-Therapeutics-to-Participate-in-the-ROTH-4th-Annual-Healthcare-Opportunities-Conference.html

GLOBENEWSWIRE
01 Oct 2025

https://www.globenewswire.com/news-release/2025/09/25/3156746/0/en/Medicenna-Announces-Results-of-Annual-Meeting-of-Shareholders.html

GLOBENEWSWIRE
25 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty